Intra-operative Optical Imaging With MDX1201-A488 in Patients With Prostate Cancer
This pilot clinical trial studies the best dose of anti-prostate specific membrane antigen (PSMA) monoclonal antibody MDX1201-A488 (MDX1201-A488) given before surgery to aid in visualization of the prostate. Attaching a fluorescence, a substance that emits radiation that is visible, to the anti-PMSA antibody and injecting it into the body may help identify the tumor when specialized microscopes are used.
|Condition or Disease||Intervention/Treatment||Phase|
PRIMARY OBJECTIVES: I. Determine the preferred imaging dose (if any), based on image quality and correlation with pathological findings, of intravenously administered MDX1201-A488 in a dose-escalating study (doses of 5 and 15 mg) in patients with moderate to high-risk prostate cancer prior to undergoing robotic assisted laparoscopic prostatectomy (RALP), subject to predetermined safety stopping rules.
SECONDARY OBJECTIVES: I. Correlate intra-operative optical imaging (IOOI) findings with pre-operative magnetic resonance imaging (MRI) findings and clinical staging.
OUTLINE: This is a dose-escalation study. Patients receive anti-PSMA monoclonal antibody MDX1201-A488 intravenously (IV) over 30 minutes on day 1 and undergo IOOI during RALP on day 5.
After completion of study treatment, patients are followed up at 4-7 weeks, 3 months, 6 months, 9 months, and 1 year.
Arms and Interventions
|Experimental: Diagnostic (MDX1201-A488, IOOI, RALP)|
Patients receive anti-PSMA monoclonal antibody MDX1201-A488 IV over 30 minutes on day 1 and undergo IOOI during RALP on day 3.
Biological: anti-PSMA monoclonal antibody MDX1201-A488
Procedure: robot-assisted laparoscopic surgery
Other: diffuse optical imaging
Other: pharmacological study
Other: Laboratory Biomarker
Primary Outcome Measures
- Imaging ability of anti-PMSA monoclonal antibody MDX1201-A488 [Up to 1 year]
The main fluorescence metric will be the minimum fluorescence observed in 10 sampled high power fields from a single representative cancerous section taken per patient. Other metrics will be the mean fluorescence observed in the 10 sampled high power fields, and the median fluorescence observed. The minimum fluorescence is chosen based on the concept that the primary focus is on observing the fluorescence, and areas of peak fluorescence greatly influence the mean, and also have some influence on the median, yet may be of limited relevance.
Histologically confirmed adenocarcinoma of the prostate; patients with small cell, neuroendocrine, and transitional cell carcinomas are not eligible
Patients being considered for RALP and pelvic lymphadenectomy with life expectancy greater than 10 years as determined by treating physician
Patients with moderate to high-risk disease as defined by D' Amico risk stratification and having at least one of the following:
Prostate-specific antigen (PSA) level > 10 ng/ml
Gleason score >= 7
Clinical stage >= T2c
Any performance status on the Eastern Cooperative Oncology Group (ECOG)
Men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation
Bone scan without evidence of skeletal metastases
Skeletal x-ray film or MRI confirmation of absent skeletal metastases if bone scan findings are equivocal
3Tesla (T) multiparametric MRI of the prostate performed at City of Hope (COH) within 6 week time period prior to surgery; MRI without evidence of bladder neck involvement, rectal wall involvement, or pelvic lymphadenopathy with no nodes > 1 cm
White blood cell (WBC) within normal limits
Hemoglobin (hgb) > 10 G/dL
Platelet count (PLT) > 100 K/uL
Creatinine clearance within normal limits
Serum glutamic oxaloacetic transaminase (SGOT) < 1.5 x upper limit of normal (ULN)
Serum glutamate pyruvate transaminase (SGPT) < 1.5 x ULN
Bilirubin < 1.5 x ULN
All subjects must have the ability to understand and the willingness to sign a written informed consent
Patients should not have any uncontrolled illness including ongoing or active infection
Prior treatment of prostate cancer including brachytherapy, radiation therapy, cryosurgery, high-intensity focused ultrasound (HIFU), or vaccine therapy
Prior pelvic surgery or radiation
Urinary incontinence requiring condom catheter use or >= 1 pad/day
Prior anti-incontinence surgery
Use of neoadjuvant hormonal manipulation
History of active co-existing non-prostatic malignancies except basal cell skin cancer or squamous cell skin cancer
Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study
Contacts and Locations
|1||City of Hope Medical Center||Duarte||California||United States||91010|
Sponsors and Collaborators
- City of Hope Medical Center
- National Cancer Institute (NCI)
- Principal Investigator: Ali Zhumkhawala, MD, City of Hope Medical Center
Study Documents (Full-Text)None provided.